LILRB1 and B-cell chronic lymphocytic leukemia: In vitro studies have shown that even mAbs blocking ILT2/CD85j, highly expressed in CLL-derived NK cells, are able in combination with the immunomodulatory drug lenalidomide to restore NK cell cytotoxicity, resulting in increased elimination of CLL cells [178].